Jade Biosciences, a burgeoning developer specializing in immune disease drugs, has set its sights on accelerating its market presence through a reverse merger with Aerovate Therapeutics. This strategic consolidation will enable Jade to promptly enter the public market under the Nasdaq ticker
Neurogene, a trailblazer in the gene therapy field concentrating on rare neurological diseases, has successfully clinched $200 million through a private funding deal designed to extend its financial runway until late 2027. This financing structure, recognized as a PIPE financing (Private Investment
Digital Polymerase Chain Reaction (PCR), especially Droplet Digital PCR (ddPCR) technology developed by Bio-Rad, has revolutionized the landscape of nucleic acid quantification, offering unmatched precision, sensitivity, and absolute quantification of nucleic acids. This third generation of PCR
Roche is considering seeking accelerated approval for its experimental Alzheimer’s drug, trontinemab, following promising early results. Trontinemab is currently in Phase 2 testing and has shown significant potential in reducing amyloid levels in the brain. This approach has been previously
Novo Nordisk recently announced its intention to seek regulatory approval for the use of semaglutide, the active ingredient in its profitable weight loss drug, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). This decision came after a Phase 3 clinical trial yielded
In a landmark event for Denmark’s technology landscape, the nation's first AI supercomputer, Gefion, has been officially inaugurated. This momentous occasion promises to expedite drug discovery and address a variety of societal challenges. The Novo Nordisk Foundation, a principal player in the
